The MIRACLE trial will evaluate Annamycin in combination with Cytarabine for patients with AML who have not responded to or have relapsed after initial therapy. The study employs an adaptive ...

This early unblinding will involve 30 participants receiving the combination of annamycin and cytarabine ... gains approval for enrolment in trial of AML therapy in Ukraine" was originally ...

allowing a reduced Phase 3 trial size for Annamycin with Cytarabine also known as AnnAraC in treating R/R AML patients. The global "MIRACLE" trial will span the US, Europe, and the Middle East.

Marlise R. Luskin, MD, MSCE, discussed treatment options for blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and ...

Actimab-A is a humanized anti-CD33 antibody conjugated to Actinium-225 (Ac-225). With its potent alpha-particle payload ...

has received first country regulatory approval in Europe to begin recruiting for its Phase 3 pivotal trial protocol evaluating Annamycin in combination with Cytarabine for the treatment of AML ...

in Part A of the trial to receive high dose cytarabine (HiDAC) combined with either placebo, 190 mg/m2 of Annamycin, or 230 mg/m2 of Annamycin, which Annamycin doses were specifically recommended ...

For example, investigational agents undergoing development for use in AML include FLT3 inhibitors, polo-like kinase inhibitors, farnesyltransferase inhibitors, HSP90 inhibitors, Mdm2 inhibitors ...

Annamycin currently has Fast Track Status and Orphan Drug Designation from the FDA for the treatment of relapsed or refractory acute myeloid leukemia, in addition to Orphan Drug Designation for ...

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company") a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today ...